Home | Structured Search | Drug Resource
Find: within
Acute Viral Conjunctivitis > Diagnosis Author: Stephen Orlin, MD
Module updated - 2008-04-08
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Superficial punctate keratitis is a common clinical feature of viral conjunctivitis (adenoviral more than picornaviral) and is associated with photophobia, foreign body sensation, and occasionally severe pain.
  • Short incubation period (<24 h), rapid onset of symptoms (<5 h), and bilateral infection are common clinical features of picornavirus (enteroviral and coxsackievirus) infection, whereas incubation period and onset of symptoms is longer in adenoviral infection.
  • Conjunctivitis caused by adenoviruses or picornaviruses is highly contagious.
  • Muscle weakness may be associated with picornaviral conjunctivitis.
  • Itching is more common in allergic conjunctivitis but may present in viral conjunctivitis.
  • HSV may present without skin leasions in an identical way to adenovirus 4% to 5% of the time.

Evidence:

  • Historical features associated with viral conjunctivitis are discussed in review articles (1; 2) and in book chapters about diseases of the outer eye (3; 4).
  • A review of virologic and clinical studies of 478 patients with acute follicular conjunctivitis in Japan concluded that it is difficult clinically to differentiate HSV conjunctivitis from adenoviral conjunctivitis. There may be a biological difference between HSV strains causing keratitis and conjunctivitis (5).

Comments:

  • A history of contact lens use or rheumatologic disease can suggest a more serious underlying pathology. Studies suggest that it is often difficult to differentiate viral from bacterial or allergic disease by the clinical exam. Clinical accuracy of about 40% to 70% compared to laboratory confirmation has been shown (6; 7; 8; 9).

FAQs
Robert Sambursky, MD, editorial consultant, Chief Medical Officer for Rapid Pathogen Screening, Inc.;served as consultant for Rapid Pathogen Screening, Inc.;received an honoraria for Rapid Pathogen Screening, Inc.;serves as consultant for Rapid Pathogen Screening, Inc; owns stock options in Rapid Pathogen Screening, Inc.;served as board member or director for Rapid Pathogen Screening, Inc.;received grants and has grants pending from Rapid Pathogen Screening, Inc.;and has received patents and has patents pending for Rapid Pathogen Screening, Inc. Stephen Orlin, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.